Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Del Mastro
L
L
Department of Medical Oncology. Electronic address: lucia.delmastro@istge.it.
Bighin
C
C
Department of Medical Oncology.
Bini
G
G
Department of Medical Oncology.
Giraudi
S
S
Department of Medical Oncology.
Taveggia
P
P
Department of Medical Oncology.
Levaggi
A
A
Department of Medical Oncology.
Canavese
G
G
Department of Surgical Oncology.
Rescinito
G
G
Department of Radiology, National Cancer Research Institute, Genoa, Italy.
Pronzato
P
P
Department of Medical Oncology.
D018943:Anthracyclines / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human